Comparative flow cytometric analysis of MZB (CD19 + CD23 low CD21/35 high ) and FoB (CD19 + CD23 high CD21/35 low ) in Gclc fl/fl Mb1-Cre + and control mice showed that Gclc deletion caused a stark decrease in MZB but not in FoB (Fig
This creates an exclusion zone (EZ) free of solute particles, that can extend some several hundred microns back from the surface
10.1007/s11033-021-06833-9 85 ThongkittidilokC.LeQ
Youm, Y-H
However, patients with low BSA psoriasis and burdensome symptoms who are candidates for biologic therapy (according to the clinicians judgement) may not meet a payers criteria for eligibility to receive advanced psoriasis treatment options [4, 9, 23, 28] Current International Psoriasis Council (IPC), American Academy of Dermatology, and National Psoriasis Foundation treatment guidelines recommend that indicators of psoriasis disease burden beyond BSA, including involvement of high-impact sites and failure of topical therapies, be considered when determining whether patients are eligible for systemic treatment [3, 4]
Any haziness warrants concern and likely disposal
